Ilaris NIS in Korea

Launched by NOVARTIS PHARMACEUTICALS · Feb 14, 2025

Keywords

ClinConnect Summary

The Ilaris NIS in Korea clinical trial is designed to evaluate the safety and effectiveness of a medication called Ilaris for patients with specific types of hereditary periodic fever syndromes, such as Cryopyrin-associated periodic syndromes (CAPS) and colchicine-resistant familial Mediterranean fever (crFMF), among others. This study will include both children and adults who have already started treatment with Ilaris or agree to receive it as part of their care.

To be eligible for this trial, participants must be aged between 2 and 19 years for certain conditions, or 19 years and older for others, and must provide consent from themselves or their legal representatives. It's important to note that this trial is currently not recruiting participants yet, so it’s still in the planning stage. Those who join will be monitored closely to ensure the treatment is safe and effective for their specific conditions. If you or a loved one are considering participation, it is essential to discuss this with your healthcare provider to understand if it’s the right choice for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent/assent of the patient or their legal representative/parent (≥2 year and \<19 year-old pediatric patient) for voluntarily participating in this study
• • 2. Age: ≥2 year and \<19 year-old pediatric and ≥19 year-old adult hereditary periodic fever syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) patients and ≥2 year and \<19 year-old sJIA patients
• • 3. Patient who have an agreement to be treated or who have already started treatment with Ilaris in accordance with the approved label information
• Exclusion Criteria:
• • 1. Patients receiving Ilaris treatment for autoimmune disease other than CAPS, crFMF, TRAPS, HIDS/MKD or sJIA
• • 2. Patients participating in an interventional clinical trial which would have an impact on routine clinical treatment